AMGN Looks 18.3% Overvalued on GF Value™ as Dividend Sustainability Remains Solid

As reported by gurufocus.com

On August 31, 2026, Amgen Inc (NASDAQ: AMGN) announced compelling results from the Phase 3 VESALIUS-CV trial showing that its cholesterol-lowering drug Repatha ...

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on gurufocus.com ↗

Market Samachar is a news aggregator. This article was originally published by gurufocus.com. Tap the button above to read the full story on their site.

INDIAN US stocks slip after Gulf clashes lift crude oil prices mint - markets
INDIAN Stock Market prediction tomorrow, September 1: What will happen to Sensex, Nifty, Bank Nifty, KOSPI, Nikkei on Tuesday? mint - markets
INDIAN Deepa Jewellers IPO: Price band, lot size, GMP, listing date and other key details of ₹460 crore issue mint - markets
INDIAN Jindal Mobilitric to expand its retail network to 100 showrooms by FY28 Share Market Today
INDIAN Eco Hotels & Resorts launches 58-room hotel in Shirdi, Maharashtra Share Market Today
INDIAN July records $4.1 billion in PE/VC investments; exit value falls 83% Share Market Today
INDIAN MFs' overseas equity holdings rise 37.5% to ₹93,602 crore in FY26: RBI Share Market Today
INDIAN US Stocks Today: US stocks fall at open as Iran war escalation sends oil prices up Markets-Economic Times

AMGN Looks 18.3% Overvalued on GF Value™ as Dividend Sustainability Remains Solid

More from Market Samachar